https://commons.ufh.ac.za/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://commons.ufh.ac.za/vital/access/manager/Repository/vital:21316 Wed 12 May 2021 20:25:14 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:4144 Wed 12 May 2021 17:20:44 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:4040 Thu 13 May 2021 14:22:11 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:3927 3 h), depolymerizing the pectin backbone while releasing the inulins from within the chicory roots. Analysis of various mixtures of FOS by mass spectrometry, HPLC and ¹H-NMR was undertaken. Results indicated that MS with electrospray ionization and ¹H-NMR are capable of providing relative quantitative data of the FOS present in the mixtures. The pharmaceutical effects of various sc-FOS (0.5%, v/v) and SCFA (0.3%, v/v) on certain bacterial enzymes (β-glucuronidase, urease and β-glucosidase) associated with the formation of carcinogens were also studied. These enzyme activities were not directly influenced by the sc-FOS, but were found to be remarkably decreased by SCFA, pointing toward the prebiotic effect of FOS in intestinal microflora modulation.]]> Thu 13 May 2021 11:50:24 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:10397 Thu 13 May 2021 05:26:59 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:36690 Fri 15 Mar 2024 12:32:30 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:40457 Fri 15 Mar 2024 12:25:35 SAST ]]> https://commons.ufh.ac.za/vital/access/manager/Repository/vital:37087 1, antagonism, respectively. Most combination treatments showed to have an antagonistic effect except for cisplatin:BC-7 (1:3, 1:1, 2:1, 3:1) and cisplatin:A. afra (1:3, 1:2, 1:1, 3:1) combinations that showed synergism. The 1:2 ratio of cisplatin:BC-7 and the 2:1 ratio of cisplatin:A. afra were additive. CI values were also calculated at inhibition of 10, 25 and 75% of HeLa cell growth, for each combination mixture. Antagonistic effects were frequently observed at lower effect levels such as at 10 and 25% inhibition of growth. However, this was not seen for the cisplatin:BC-7 combinations as all the ratios indicated synergism. Some of these ratios, such as the 1:3 and 1:2, even led to a greater degree of synergism being obtained, with noticeable antagonistic effects seen at 50 and 75% inhibition of growth. The current finding is that BC-7 and A. afra could lower the dose of cisplatin in combination to achieve a similar anti-cancer efficacy compared to the higher cisplatin dose when used alone. The lower dosage in combination could result in reduced drug resistance as well as limit the toxicity on normal cells associated with cisplatin treatment. In conclusion, this study shows, for the first time, that A. nemorosa has the potential to induce apoptosis and also has some anti- and pro-inflammatory activity in HeLa cancer cells. This study also enhanced the knowledge of the mechanism of apoptosis induction of BC-7, in a more detailed manner, as well as investigated its inflammatory effects for the first time. Results obtained for A. afra correlated nicely to previously reported studies and confirmed that the methods used in this study, although different, leads to the same conclusions. Combination treatments also indicated, for the first time, that BC-7 and A. afra have the ability to function in a synergic manner with cisplatin and proves that, although extensive research may have been done on a plant or compound, more can be discovered. This new information can lead to identification of new compounds in the plants and the integration of signalling pathways that can be targeted for treatment of cancer.]]> Fri 15 Mar 2024 11:56:53 SAST ]]>